A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
Status:
Completed
Trial end date:
2015-12-03
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to assess the non-inferior antiviral activity of GSK1349572 50
mg plus Abacavir/Lamivudine once daily versus Efavirenz/Emtricitabine/Tenofovir disoproxil
fumarate (ATRIPLA® a trade mark of Bristol-Myers Squibb and Gilead Sciences LLC) over 48
weeks; non-inferiority will also be tested at Week 96. This study will be conducted in HIV-1
infected ART-naïve adult subjects. Long term antiviral activity, tolerability, safety, and
development of viral resistance will be evaluated.